Medpace downgraded to Sell from Neutral at UBS

UBS analyst Dan Leonard downgraded Medpace (MEDP) to Sell from Neutral with a price target of $305, up from $300. The firm views the company’s near- and mid-term targets as “overly ambitious” against a “weak “industry backdrop. Medpace’s Q2 bookings improved materially, but further improvement towards Street estimates and the company’s targets would require record bookings in the second half of 2025 despite weak biotech capital markets, clinical trial starts, muted hiring, and other cautionary signals, the analyst tells investors in a research note.